![Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/37909.jpg)
Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate
![Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer](https://www.frontiersin.org/files/MyHome%20Article%20Library/779030/779030_Thumb_400.jpg)
Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer
![Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/328286526/figure/fig2/AS:682002189660161@1539613401325/Overall-survival-curve-by-treatment-method-The-5-year-overall-survival-rate-and-median.png)
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
![Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-06738-z/MediaObjects/12885_2020_6738_Fig3_HTML.png)
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
![5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO 5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO](https://www.bjmo.be/app/uploads/2021/11/Banner-KN024-EN-V1-2400x1800-NOV21.jpg)
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
![Significant 5-year overall survival following neoadjuvant nivolumab in lung cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe Significant 5-year overall survival following neoadjuvant nivolumab in lung cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2023/02/Significant-5-year-overall-survival-following-neoadjuvant-nivolumab-in-lung-cancer.jpg)
Significant 5-year overall survival following neoadjuvant nivolumab in lung cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe
![Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer](https://ecancer.org/en/journal/article/site/data/images/article/1010/can-14-1005fig6.gif)
Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer
![Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12957-021-02478-x/MediaObjects/12957_2021_2478_Fig1_HTML.png)
Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text
![Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9dac71d5-2807-47b8-bda8-e805fbd64fa3/ajh26156-fig-0003-m.jpg)
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library
![Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11255-019-02181-7/MediaObjects/11255_2019_2181_Fig1_HTML.png)
Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink
![Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10120-017-0716-7/MediaObjects/10120_2017_716_Fig3_HTML.gif)
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink
![Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram](https://www.researchgate.net/publication/333780703/figure/fig1/AS:769686505541634@1560518971977/Kaplan-Meier-survival-curves-comparing-5-year-overall-survival-OS-and-recurrence-free.png)
Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f29f5c3e-5a9b-447a-8641-63022e061899/gr1_lrg.gif)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![4baseCare on Twitter: "Research data suggests that 5-year survival rates in different subtypes of Cholangiocarcinoma vary in different stages of the disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9" / Twitter 4baseCare on Twitter: "Research data suggests that 5-year survival rates in different subtypes of Cholangiocarcinoma vary in different stages of the disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9" / Twitter](https://pbs.twimg.com/media/FPpvkhUaIAAqXds.jpg)
4baseCare on Twitter: "Research data suggests that 5-year survival rates in different subtypes of Cholangiocarcinoma vary in different stages of the disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9" / Twitter
![Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-85223-4/MediaObjects/41598_2021_85223_Fig1_HTML.png)
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086418309353-gr1.jpg)